An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials
J MacDougall(Ironwood Pharmaceuticals (United States)), Anthony J Lembo(Beth Israel Deaconess Medical Center), Richard T. Carson(University of California, San Diego), J. Martin Johnston(Ironwood Pharmaceuticals (United States)), Bernard J. Lavins(Ironwood Pharmaceuticals (United States)), Lauren Nelson(RTI Health Solutions), S. J. Shiff(Forest Research Institute), M Currie(Ironwood Pharmaceuticals (United States)), M. J. Baird(Ironwood Pharmaceuticals (United States)), CB Kurtz(Ironwood Pharmaceuticals (United States)), Kelvin Shi(Deciphera Pharmaceuticals (United States)), Valerie Williams(RTI International)
Cited by 30
Related Papers
Contingent Valuation: A Practical Alternative when Prices Aren't Available
|The Journal of Economic Perspectives|2012|531
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2020|406
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
|British Journal of Dermatology|2019|384
Assessing test–retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula
|Quality of Life Research|2018|247
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)
|Current Medical Research and Opinion|2019|138